Clinical trialNCT00038818TerminatedInterventional

CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

SponsorM.D. Anderson Cancer CenterEnrollment3Chronic Lymphocytic LeukemiaChronic Myelogenous LeukemiaHodgkin's DiseaseMultiple MyelomaNon Hodgkin's Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Richard Champlin, MD, BS
UT MD Anderson Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ut Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CD8 Depleted Donor Lymphocyte

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2001
Primary completion: 31 Dec 2002
Completion: 31 Dec 2002
Last update posted: 23 Aug 2012
Registered enrollment: 3
Registry id: NCT00038818

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.